|
KR20150109429A
|
|
Fluoro-[1,3]oxazines as bace1 inhibitors
|
|
EP2878339A1
|
|
SIP3 antagonists
|
|
AU2013202820A1
|
|
2-Amino-5, 5-difluoro-5, 6-dihydro-4H-oxazines as BACE 1 and/or BACE 2 inhibitors
|
|
TW201323407A
|
|
Process for the preparation of 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and intermediates thereof
|
|
BR112014009297A2
|
|
processes for the preparation of 6-chloro-2,3,4,9-tetrahydro-1 h-carbazole-1-carboxamide and its precursors
|
|
TW201247629A
|
|
Wnt pathway antagonists
|
|
WO2012136492A1
|
|
Wnt pathway antagonists
|
|
TW201305128A
|
|
Compound for the treatment of tumours and tumour metastases
|
|
CA2805867A1
|
|
1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
|
|
KR20120104598A
|
|
2-amino-5,5-difluoro-5,6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors
|
|
EP2468726A1
|
|
Compound for the treatment of tumours and tumour metastases
|
|
TW201118081A
|
|
Wnt pathway antagonists
|
|
KR20120026534A
|
|
Hedgehog pathway antagonists and therapeutic applications thereof
|
|
AU2008335880A1
|
|
Hedgehog pathway antagonists and therapeutic applications thereof
|
|
CN101374810A
|
|
Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
|
|
BRPI0706610A2
|
|
nicotinically acetylcholine alpha 7 receptor modulators and therapeutic uses of these
|
|
WO2007082731A1
|
|
Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
|
|
ZA200700527B
|
|
Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
|
